Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. First Tracks Biotherapeutics's Enterprise Value for Today is $978.05 Mil.
First Tracks Biotherapeutics (NAS:TRAX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
First Tracks Biotherapeutics Market Cap Related Terms
First Tracks Biotherapeutics Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
First Tracks Biotherapeutics Market Cap Chart
First Tracks Biotherapeutics Annual Data
Trend
Dec23
Dec24
Market Cap
0.00
0.00
First Tracks Biotherapeutics Semi-Annual Data
Dec23
Dec24
Market Cap
0.00
0.00
TRAX vs ALT, RGNX, MDXG: Market Cap Comparison
For the Biotechnology subindustry, First Tracks Biotherapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
First Tracks Biotherapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, First Tracks Biotherapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where First Tracks Biotherapeutics's Market Cap falls into.
First Tracks Biotherapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
First Tracks Biotherapeutics (TRAX) has a Market Cap of $1,264.50 Mil as of Jul. 13, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on First Tracks Biotherapeutics and its competitors. According to the industry distribution chart, First Tracks Biotherapeutics ranks #248 out of 1423 companies in the Biotechnology industry, placing it in the top 17.4%.
Is First Tracks Biotherapeutics' Market Cap too high?
First Tracks Biotherapeutics' current Market Cap is $1,264.50 Mil. The Biotechnology industry median Market Cap is 121.30. First Tracks Biotherapeutics' value of $1,264.50 Mil is 942.4% above this industry median. Based on the distribution chart, First Tracks Biotherapeutics ranks #248 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, First Tracks Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Market Cap compare to ALT and RGNX?
According to the Biotechnology industry distribution chart, First Tracks Biotherapeutics ranks #248 out of 1423 companies for Market Cap. This places First Tracks Biotherapeutics in the top 17% of its industry — outperforming the majority of peers. The industry median Market Cap is 121.30. First Tracks Biotherapeutics' value of $1,264.50 Mil is 942.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.30, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. First Tracks Biotherapeutics's current Market Cap of $1,264.50 Mil is 942.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on First Tracks Biotherapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 121.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. First Tracks Biotherapeutics's current Market Cap is $1,264.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (TRAX) has a current Market Cap of $1,264.50 Mil. The current Market Cap is $1,264.50 Mil and 942.4% above the Biotechnology industry median of 121.30. First Tracks Biotherapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For First Tracks Biotherapeutics (TRAX), the current Market Cap is $1,264.50 Mil as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score
Get the complete analysis for TRAX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRAX has been successfully added to your 